Tags

Type your tag names separated by a space and hit enter

Minocycline-induced reduction of brain-derived neurotrophic factor expression in relation to cancer-induced bone pain in rats.
J Neurosci Res. 2012 Mar; 90(3):672-81.JN

Abstract

Previous studies have suggested that the release of brain-derived neurotrophic factor (BDNF) from microglia in spinal cord is necessary for maintaining pain hypersensitivity after nerve injury. However, little is known about its role in cancer-induced bone pain (CIBP), which is in some ways unique. This study demonstrates a critical role of minocycline (a potent inhibitor of microglial activation)-modulated BDNF in the induction and maintenance of behavioral hypersensitivity in a rat model of CIBP. We assessed mechanical threshold and spontaneous pain of CIBP rats. Moreover, minocycline was administered intrathecally from day 4 to day 6 (early stage) or from day 10 to day 12 (later stage), after carcinoma cell inoculation. Real-time PCR, Western blots, and double immunofluorescence were used to detect the expression of OX-42 (marker of activated microglia), phosphorylated p38-MAPK (p-p38), and BDNF. We found that intrathecal minocycline could prevent CIBP at an early stage of tumor growth (from day 4 to day 6). However, at the late stage (from day 10 to day 12), intrathecal minocycline had no effect. Moreover, the expression of OX-42 and BDNF under CIBP, peaking on day 6, were all reduced after minocycline injection from day 4 to day 6. The ability of minocycline-induced reduction of BDNF in the induction of behavioral hypersensitivity could provide an opportunity for alleviating CIBP.

Authors+Show Affiliations

Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22057846

Citation

Wang, Li-Na, et al. "Minocycline-induced Reduction of Brain-derived Neurotrophic Factor Expression in Relation to Cancer-induced Bone Pain in Rats." Journal of Neuroscience Research, vol. 90, no. 3, 2012, pp. 672-81.
Wang LN, Yang JP, Zhan Y, et al. Minocycline-induced reduction of brain-derived neurotrophic factor expression in relation to cancer-induced bone pain in rats. J Neurosci Res. 2012;90(3):672-81.
Wang, L. N., Yang, J. P., Zhan, Y., Ji, F. H., Wang, X. Y., Zuo, J. L., & Xu, Q. N. (2012). Minocycline-induced reduction of brain-derived neurotrophic factor expression in relation to cancer-induced bone pain in rats. Journal of Neuroscience Research, 90(3), 672-81. https://doi.org/10.1002/jnr.22788
Wang LN, et al. Minocycline-induced Reduction of Brain-derived Neurotrophic Factor Expression in Relation to Cancer-induced Bone Pain in Rats. J Neurosci Res. 2012;90(3):672-81. PubMed PMID: 22057846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Minocycline-induced reduction of brain-derived neurotrophic factor expression in relation to cancer-induced bone pain in rats. AU - Wang,Li-Na, AU - Yang,Jian-Ping, AU - Zhan,Ying, AU - Ji,Fu-Hai, AU - Wang,Xiu-Yun, AU - Zuo,Jian-Ling, AU - Xu,Qi-Nian, Y1 - 2011/11/04/ PY - 2011/06/07/received PY - 2011/08/06/revised PY - 2011/08/16/accepted PY - 2011/11/8/entrez PY - 2011/11/8/pubmed PY - 2012/7/20/medline SP - 672 EP - 81 JF - Journal of neuroscience research JO - J. Neurosci. Res. VL - 90 IS - 3 N2 - Previous studies have suggested that the release of brain-derived neurotrophic factor (BDNF) from microglia in spinal cord is necessary for maintaining pain hypersensitivity after nerve injury. However, little is known about its role in cancer-induced bone pain (CIBP), which is in some ways unique. This study demonstrates a critical role of minocycline (a potent inhibitor of microglial activation)-modulated BDNF in the induction and maintenance of behavioral hypersensitivity in a rat model of CIBP. We assessed mechanical threshold and spontaneous pain of CIBP rats. Moreover, minocycline was administered intrathecally from day 4 to day 6 (early stage) or from day 10 to day 12 (later stage), after carcinoma cell inoculation. Real-time PCR, Western blots, and double immunofluorescence were used to detect the expression of OX-42 (marker of activated microglia), phosphorylated p38-MAPK (p-p38), and BDNF. We found that intrathecal minocycline could prevent CIBP at an early stage of tumor growth (from day 4 to day 6). However, at the late stage (from day 10 to day 12), intrathecal minocycline had no effect. Moreover, the expression of OX-42 and BDNF under CIBP, peaking on day 6, were all reduced after minocycline injection from day 4 to day 6. The ability of minocycline-induced reduction of BDNF in the induction of behavioral hypersensitivity could provide an opportunity for alleviating CIBP. SN - 1097-4547 UR - https://www.unboundmedicine.com/medline/citation/22057846/Minocycline_induced_reduction_of_brain_derived_neurotrophic_factor_expression_in_relation_to_cancer_induced_bone_pain_in_rats_ L2 - https://doi.org/10.1002/jnr.22788 DB - PRIME DP - Unbound Medicine ER -